Moderate Evidence (L3-L4)
Candidates with preliminary evidence that require further validation
Criteria
| Level | Definition | Clinical meaning |
|---|---|---|
| L3 | Observational studies / large case series | Preliminary support; needs further validation |
| L4 | Preclinical / mechanistic studies | Theoretical support; far from clinical use |
L3 (39 drugs)
| Drug | Indications | Link |
|---|---|---|
| Acitretin | 4 | View report |
| Adalimumab | 6 | View report |
| Atenolol | 9 | View report |
| Axitinib | 10 | View report |
| Brentuximab Vedotin | 10 | View report |
| Bumetanide | 1 | View report |
| Calcipotriol | 10 | View report |
| Captopril | 4 | View report |
| Carbamazepine | 10 | View report |
| Cefazolin | 8 | View report |
| Chlorambucil | 8 | View report |
| Clonazepam | 3 | View report |
| Efavirenz | 3 | View report |
| Etanercept | 6 | View report |
| Etravirine | 10 | View report |
| Famotidine | 10 | View report |
| Itraconazole | 1 | View report |
| Ketamine | 1 | View report |
| Ketoconazole | 1 | View report |
| Lacosamide | 10 | View report |
| Lamivudine | 5 | View report |
| Levothyroxine | 10 | View report |
| Lisinopril | 10 | View report |
| Methenamine | 4 | View report |
| Moxifloxacin | 10 | View report |
| Nicorandil | 7 | View report |
| Norfloxacin | 10 | View report |
| Nystatin | 10 | View report |
| Omalizumab | 10 | View report |
| Omeprazole | 2 | View report |
| Posaconazole | 1 | View report |
| Prednisone | 10 | View report |
| Progesterone | 10 | View report |
| Rifampicin | 10 | View report |
| Rizatriptan | 2 | View report |
| Sucralfate | 2 | View report |
| Tenofovir Disoproxil | 4 | View report |
| Teriparatide | 10 | View report |
| Zidovudine | 6 | View report |
L4 (48 drugs)
| Drug | Indications | Link |
|---|---|---|
| Allopurinol | 10 | View report |
| Aminophylline | 10 | View report |
| Baclofen | 2 | View report |
| Bicalutamide | 10 | View report |
| Budesonide | 10 | View report |
| Ceftriaxone | 7 | View report |
| Ciprofloxacin | 10 | View report |
| Clarithromycin | 5 | View report |
| Clobazam | 10 | View report |
| Clofazimine | 3 | View report |
| Clotrimazole | 3 | View report |
| Colchicine | 3 | View report |
| Dolutegravir | 3 | View report |
| Doxazosin | 2 | View report |
| Doxycycline | 10 | View report |
| Droperidol | 10 | View report |
| Entecavir | 10 | View report |
| Eplerenone | 5 | View report |
| Erythromycin | 5 | View report |
| Etoposide | 10 | View report |
| Febuxostat | 3 | View report |
| Flucloxacillin | 10 | View report |
| Fluticasone | 3 | View report |
| Folic Acid | 1 | View report |
| Labetalol | 4 | View report |
| Levocabastine | 2 | View report |
| Levonorgestrel | 6 | View report |
| Mepolizumab | 5 | View report |
| Miconazole | 1 | View report |
| Misoprostol | 2 | View report |
| Modafinil | 1 | View report |
| Nevirapine | 3 | View report |
| Nilotinib | 1 | View report |
| Nintedanib | 3 | View report |
| Norethisterone | 1 | View report |
| Perindopril | 5 | View report |
| Pregabalin | 6 | View report |
| Propylene Glycol | 10 | View report |
| Propylthiouracil | 3 | View report |
| Quetiapine | 10 | View report |
| Ribociclib | 4 | View report |
| Ritonavir | 3 | View report |
| Roxithromycin | 8 | View report |
| Sumatriptan | 1 | View report |
| Tetracycline | 4 | View report |
| Tobramycin | 10 | View report |
| Tranexamic Acid | 1 | View report |
| Tyrosine | 10 | View report |
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)